← Leaderboards
Al Hawkins
Zvelt Therapeutics Inc.
$784,047
Attributed
$1,568,094
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$1,568,094 · 3
By mechanism
R42$1,274,252 · 2
R41$293,842 · 1
Top collaborators
- Lei Cao2 shared
- Youngmok Lee1 shared
Others in their field
Other Rising Stars on “Transgenes”
- John Alam · Eip Pharma, Inc.$10,411,018
- Amanda L. Woerman · University Of Massachusetts Amherst$4,303,175
- Baodong Sun · Duke University$3,238,660
- Courtney Cohen · Albert Einstein College Of Medicine$3,193,054
- Victoria Eleanor Johnson · University Of Pennsylvania$3,102,638
- Jessica Boyle · University Of Iowa$2,844,441
Research focus
TransgenesGene TherapySerotypingUniversitiesNovel TherapeuticsLiverMetabolic DiseasesPre-ClinicalToxicologyDoseTechnologySmall Business Technology Transfer ResearchFatty Acid Glycerol EstersMouse ModelBiodistributionEuropeAustraliaAffectEngineeringGenesCellsCardiacDiagnosisAdverse Effects
Grant awards (3)
Novel Adipose Targeted Gene Therapy for Lipodystrophy$974,604
R42 · FY2025 · DK · contact PI
ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b$299,648
R42 · FY2025 · DK · contact PI
Novel Adipose Targeted Gene Therapy for Lipodystrophy$293,842
R41 · FY2023 · DK · contact PI